The international surgical journal with global reach

This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191-1203.

Published: 1st July 2021

Authors: Kelly RJ, Ajani JA, Kuzdzal J, Zander T, van Cutsem E, Piessen G et al.

Conclusion

This study included 794 patients followed for a median of 24.4 months. The addition of nivolumab for up to a year improved disease-free survival from a median of 11 to 22.4 months, hazard ratio 0.69, 95 per cent confidence interval 0.56 to 0.86, P<0.001. Nivolumab was discontinued in 9 per cent of patients for adverse events.

Pubmed Link